Table 4.
Factors Associated with an Improvement in the Gastroesophageal Reflux Symptoms after Changing Therapy (n=26).
| Variable | Improved/Not improved | OR (95% CI) | p value | |||
|---|---|---|---|---|---|---|
| Age, years | 68.6/65.0* | 1.03 (0.96-1.10) | 0.481 | |||
| Sex, male | 5/2 | 1.15 (0.17-7.74) | 0.883 | |||
| BMI, kg/m2 | 22.4/22.0* | 1.04 (0.78-1.40) | 0.787 | |||
| Current alcohol consumption | 5/1 | 2.69 (0.26-27.8) | 0.406 | |||
| Current smoker | 0/1 | NA | NA | |||
| Pre-treatment PPI | ||||||
| Rabeprazole | 8/3 | 1.33 (0.24-7.35) | 0.741 | |||
| Lansoprazole | 4/2 | 0.86 (0.12-6.01) | 0.877 | |||
| Omeprazole | 1/0 | NA | NA | |||
| Esomeprazole | 5/3 | 0.64 (0.11-3.74) | 0.621 | |||
| Concomitant drug use | ||||||
| Histamine 2 receptor antagonists | 0/0 | NA | NA | |||
| Mucoprotective agents | 5/2 | 1.15 (0.17-7.74) | 0.883 | |||
| Low-dose aspirin | 2/1 | 0.88 (0.07-11.3) | 0.919 | |||
| NSAIDs | 2/3 | 0.21 (0.03-1.62) | 0.134 | |||
| Anticoagulants | 2/0 | NA | NA | |||
| Thienopyridine | 1/0 | NA | NA | |||
| Vonoprazan adherence (%) | 88.6/93.4* | 0.97 (0.89-1.07) | 0.540 | |||
| Endoscopic findings | ||||||
| Hiatus hernia | 5/2 | 1.25 (0.19-8.44) | 0.819 | |||
| Endoscopic gastric mucosal atrophy | 8/5 | 0.48 (0.09-2.65) | 0.399 | |||
| H. pylori status | ||||||
| Uninfected or eradicated | 10/3 | 1.00 | ||||
| Persistent infected | 8/5 | 0.48 (0.09-2.65) | 0.399 |
BMI: body mass index, CI: confidence interval, NA: not applicable, NSAIDs: non-steroidal anti-inflammatory drugs, OR: odds ratio, PPI: proton pump inhibitor
*Mean